Five years after treatment with the Optilume BPH catheter system, urinary flow rate (Qmax) improved by 63% and post-void residual volume (PVR) remained substantially lower than baseline.

A postmarketing study showed that the Optilume BPH system improved the flow of urine while leaving sexual function unchanged in men with benign prostatic hyperplasia (BPH), researchers reported at ...

Paclitaxel was hypothesized to provide additional benefit because of its urothelial penetration and use in other conditions, including the Optilume BPH drug-coated balloons for lower urinary tract ...

Optimal patient selection on the basis of prostate size, presence of a median lobe, and patient preferences is key to success for various minimally invasive surgical treatments for benign prostatic ...

Several of the novel BPH stents will be presenting their findings, along with longer-term data on Optilume BPH, Aquablation, and enucleation techniques. Additionally, the Innovation Nexus on Friday ...

Men with benign prostatic hyperplasia (BPH) appear to have higher risks for chronic kidney disease (CKD) and kidney stones. Men with benign prostatic hyperplasia (BPH) are at increased risk for ...

The results underscore the long-term durability and safety of the Optilume ® Drug-Coated Balloon (DCB) as a minimally invasive treatment for recurrent anterior urethral strictures in men.